Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Farxiga (dapagliflozin) is a once-daily prescription tablet in the SGLT2 inhibitor class that lowers blood sugar by prompting the kidneys to flush excess glucose out through the urine. It is approved to improve blood sugar control in type 2 diabetes, to reduce the risk of hospitalization and cardiovascular death in adults with heart failure, and to slow the progression of chronic kidney disease. Dosing, common side effects such as urinary tract and genital yeast infections or dehydration, rarer risks like ketoacidosis, and the reasons some people should not take it all vary by individual, so there are important details to review below before assuming it is right for you.
If you are noticing symptoms such as increased thirst, frequent urination, swelling in your legs, or unusual fatigue and are not sure whether they point toward blood sugar, heart, or kidney problems, a free,
Farxiga (dapagliflozin) is a prescription medication in a class called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by helping your kidneys remove glucose (sugar) from your bloodstream through your urine. Approved by health authorities worldwide, Farxiga offers benefits beyond blood sugar control and is now used for several related conditions.
Farxiga is first and foremost a blood sugar-lowering agent for adults with type 2 diabetes. When diet and exercise alone aren’t enough, adding Farxiga can help:
Farxiga is approved to reduce the risk of hospitalization for heart failure and cardiovascular death in adults with:
Benefits include fewer hospital visits and improved quality of life, regardless of whether you have diabetes.
In people with CKD—especially those with albuminuria or reduced filtering capacity—Farxiga has been shown to:
Always discuss your full medical history, including kidney or liver issues, with your healthcare provider.
Most side effects are mild to moderate and often diminish over time:
Stay well-hydrated, practice good hygiene, and speak to your doctor if any of these persist or worsen.
Although Farxiga is generally well tolerated, certain serious risks require attention:
Always follow your prescriber’s instructions and do not change your dose without medical advice.
Farxiga may interact with:
Inform your healthcare team about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you take.
If you’re unsure, discuss alternatives and risks with your doctor.
Regular check-ups help ensure safety and effectiveness:
Report any unusual symptoms promptly.
Farxiga works best when combined with healthy habits:
Contact emergency services or go to the nearest hospital if you experience:
For any other concerns or if new or worsening symptoms arise, speak to a doctor. You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to better understand your condition before your appointment.
Farxiga has transformed the management of type 2 diabetes, heart failure, and chronic kidney disease for many patients. Its dual action—lowering blood sugar and providing cardiovascular and renal protection—makes it a valuable option under medical supervision.
Always speak to a healthcare professional before starting, stopping, or combining medications. Never ignore professional medical advice or delay seeking it based on information you’ve read here. If you have life-threatening or serious symptoms, contact emergency services immediately.
(References)
* Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
* Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019 Jul;79(10):1135-1146. doi: 10.1007/s40265-019-01148-3. PMID: 31236801; PMCID: PMC6879440.
* McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. PMID: 31535829.
* Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30. PMID: 32877652.
* Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. PMID: 34619106.
* Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. PMID: 34619108.
* Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28. PMID: 34711976; PMCID: PMC8604725.
* Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. Epub 2024 May 1. PMID: 38696170; PMCID: PMC11066699.
* Liu Y, Chen Y, Ma J, Lin J, Liu C, Li X, Xu Y, Kuang H, Shi L, Xue Y, Feng B, Zhu D, Wang G, Yang J, Xiao X, Yu X, Zhou J, Bao Y, Su Q, Lyu M, Li X, Zhang H, Li X. Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025 Jan 22;388:e081820. doi: 10.1136/bmj-2024-081820. Epub 2025 Jan 22. PMID: 39843169; PMCID: PMC11752448.
* Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation. 2025 Nov 18;152(20):1411-1422. doi: 10.1161/CIRCULATIONAHA.125.076575. Epub 2025 Aug 29. PMID: 40884036; PMCID: PMC12910484.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.